The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.
ApexOnco Front Page
Recent articles
Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.
China's Harmoni-A trial hits on overall survival, but hopes for a global phase 3 seem optimistic.
Qilu moves its GPRC5D T-cell engager into phase 3, but trispecifics set the new pace.
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
After Dren secured buy-in from Novartis, LTZ becomes a clinical player.
New draft guidance could see the agency getting ever stricter.
mRNA-2808 could be a multispecific mRNA-encoded T-cell engager therapy.
